Table 1.
Patient and clinical characteristics with risk group stratification according to the EpSSG RMS2005 trial.
| Number of patients | |
|---|---|
| Age at diagnosis (years) | |
| <1 | 1 |
| 1–10 | 64 |
| >10 | 34 |
| Sex | |
| Female | 38 |
| Male | 61 |
| Histology | |
| Alveolar rhabdomyosarcoma | 28 |
| Botryoid rhabdoyosarcoma | 2 |
| Embryonal rhabdomyosarcoma | 67 |
| Rhabdomyosarcoma not otherwise specified | 1 |
| Spindle cell/leiomyomatous rhabdomyosarcoma | 1 |
| Pathology | |
| Favorable | 71 |
| Unfavorable | 28 |
| Postsurgical tumor staging (IRS grouping) | |
| I | 6 |
| II | 13 |
| III | 53 |
| IV | 27 |
| Tumor size | |
| ≤5 cm | 43 |
| >5 cm | 56 |
| Regional lymph node involvement | |
| No evidence of lymph node involvement | 69 |
| Evidence of regional lymph node involvement | 29 |
| No information about lymph node involvement | 1 |
| Risk group | |
| Low risk | 3 |
| Standard risk | 35 |
| High risk | 29 |
| Very high risk | 5 |
| Metastatic | 27 |
| Site of origin of primary tumor | |
| Orbit | 17 |
| Head/neck | 6 |
| Parameningeal | 21 |
| Bladder prostate | 9 |
| Genitourinary nonbladder prostate | 13 |
| Extremities | 18 |
| Other sites | 15 |